

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/584,151
		Filing Date	June 22, 2006
		First Named Inventor	Gerard MOINET et al.
		Art Unit	1625
		Examiner Name	Taofiq A. Soloja
		Attorney Docket Number	MERCK-3186
Sheet	1	of	2

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
	B1	WO 03/010146	02-06-2003	Klotz et al.	
	B2	EP 0 433 679	06-26-1991	Senju Pharma Co	
	B3	EP 0 398 283	11-22-1990	Merrell Dow Pharmac	
	B4	EP 2 791 263	09-29-2000	Malina Halina Zofia	
	B5	WO 2004/007461	01-22-2004	Prana Biotechnoloogy Ltd.	
	B6	WO 2004/045614	06-03-2004	Astrazeneca AB, et al.	

Examiner Signature	/Taofiq Solola/	Date Considered	08/11/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.⁷

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/584,151
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	June 22, 2006
				<i>First Named Inventor</i>	Gerard MOINET et al.
				<i>Art Unit</i>	1625
				<i>Examiner Name</i>	Taofiq A. Solola
Sheet	2	of	2	<i>Attorney Docket Number</i>	
MERCK-3186					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	HARRISON, BOYD L. ET AL: "4-'(CARBOXYMETHYL) OXYI-AND 4-'(CARBOXYMETHYL) AMINOI-5,7-DICHLOROQUINO LINE-2-CARBOXYLIC ACID: NEW ANTAGONISTS OF THE STRYCHNINE-INSENSITIVE GLYCINE BINDING SITE ON THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR COMPLEX" JOURNAL OF MEDICINAL CHEMISTRY, 33(12), 3130-2 CODEN: JMCMAR; ISSN: 0022-2623, 1990, XP001199578.			
	C2	SALITURO, FRANCESCO G. ET AL: "3-(2-CARBOXYINDOL-3-YL)PROPIONIC ACID-BASED ANTAGONISTS OF THE NMDA (N-METHYL-D-ASPARTIC ACID) RECEPTOR ASSOCIATED GLYCINE BINDING SITE" JOURNAL OF MEDICINAL CHEMISTRY, 35(10), 1791-9 CODEN: JMCMAR; ISSN: 0022-2623, 1992, XP001199577.			
	C3	DATABASE CHEMABS 'ONLINE! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KOTAKE, YAHITO ET AL: "XANTHURENIC ACID. XVI. INHIBITORY ACTION OF 4-HYDROXY-8-METHOXYQUINOLINE-2-CARBOXYLIC ACID, ETHEREAL SULFATE OF XANTHURENIC ACID, AND KYNURENIC ACID ON THE DIABETOGENIC PROPERTY OF XANTHURENIC ACID" XP002294269, RETRIEVED FROM STN, DATABASE ACCESSION NO. 1958:31214 ABSTRACT & JOURNAL OF BIOCHEMISTRY (TOKYO, JAPAN), 44, 787-95 CODEN: JOBIAO; ISSN: 0021-924X, 1957.			
	C4	CARVALHO ET AL: "ROLE OF ENDOGENOUS ANGIOTENSIN II ON GLUTAMATERGIC ACTIONS IN THE ROSTRAL VENTROLATERAL MEDULLA IN GOLDBLATT HYPERTENSIVE RATS" HYPERTENSION, (2003 OCT) JOURNAL CODE: 7906255. ISSN: 1524-4563; XP008034587.			
	C5	KOTAKE ET AL: "A POSSIBLE DIABETOGENIC ROLE FOR TRYPTOPHAN METABOLITES AND EFFECTS OF XANTHURENIC ACID ON INSULIN" AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 24, no. 7, JULY 1971, PAGES 826-829, XP000867441; ISSN: 0002-9165.			
	C6	SANDERS ET AL: "L-AMINO ACID INHIBITION OF EPINEPHRINE-INDUCED HYPERGLYCEMIA: PHARMACOLOGY, 6(3), 155-63 CODEN: ISSN: 0031-7012, 1971, XP008034538.			
	C7	STONE ET AL: "ENDOGENOUS KYNURENINES AS TARGETS FOR DRUG DISCOVERY AND DEVELOPMENT" NATURE REVIEWS, DRUG DISCOVERY, AUG 2002, vol. 1, no. 8, PAGES 609-620, XP008034547; ISSN: 1474-1776.			
	C8	EDMONT ET AL: "SYNTHESIS AND EVALUATION OF QUINOLINE CARBOXYGUANIDINES AS ANTIDIABETIC AGENTS" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1831-1834 CODEN: BMCLB8, ISSN: 0960-894X, 2000, XP002294268.			
	C9	NICOLAUS: "SYMBIOTIC APPROACH TO DRUG DESIGN" DECISION MAKIN IN DRUG RESEARCH, 1983, PAGES 173-186, XP002197412.			

Examiner Signature	/Taofiq Solola/	Date Considered	08/11/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./